On the effect of anorectic drugs on striatum homovanillic acid in rats

Effect of three anorectic drugs on central catecholamine levels and synthesis in the Zucker rat

1. Genetically obese Zucker rats and their lean littermates were treated during 5 days with fenfluramine, mazindol or amphetamine. Norepinephrine and dopamine levels were assayed in the hypothalamus, striatum, medulla-oblongata pons and remainder of the brain, and the amine synthesis was estimated, when possible. 2. Fenfluramine acted especially on norepinephrine in the obese rat hypothalamus. 3. Mazindol was active on norepinephrine and dopamine levels only in obese animals. 4. Amphetamine acted on norepinephrine levels only in obese rats and on dopamine levels in both obese and lean rats.

Effect of mazindol on brain dopamine turnover in spiperone-treated rats

Mazindol, an anorexic drug, caused a large increase in brain 3, 4-dihydroxyphenylacetic acid (DOPAC) concentration in spiperone-pretreated rats. The increase was dose-related over a 1--10 mg/kg dose range of mazindol and was maximum within 1 hour after maxzindol injection into rats pretreated 1 hour previously with spiperone. In spiperone-pretreated rats, mazindol accelerated the disappearance of dopamine after the inhibition of dopamine synthesis by alpha-methyltyrosine. Mazindol apparently resembles amfonelic acid, methylphenidate, and cocaine in facilitating the impulse-mediated release of dopamine.

Role of brain monoamines in the anorectic activity of mazindol and d-amphetamine in the rat

The interaction of mazindol and d-amphetamine with brain monoamines was studied in rats. At each dose used, both compounds markedly counteracted the decrease of brain noradrenaline induced by 6-hydroxydopamine while only at high doses they did significantly reduce the effect of 6-hydroxydopamine on brain dopamine. Unlike d-amphetamine, mazindol significantly counteracted the decrease of brain serotonin induced by fenfluramine. The anorectic effect of mazindol and of d-amphetamine was markedly reduced by an electrolytic lesion at the level of the ventral noradrenergic bundle but not by an electrolytic lesion of the nucleus raphe medianus. An intrastriatal injection of 6-hydroxydopamine significantly reduced the effect of mazindol but not that of d-amphetamine. The results indicate that both compounds may block noradrenaline uptake in the brain while their effect on dopamine uptake is less evident. Ulike d-amphetamine, mazindol appears to inhibit serotonin uptake also. In addition, the integrity of the noradrenergic neurons in the brain appears to be an important condition for these drugs to exert their anorectic effect.

Tolerance to the increase of striatal homovanillic acid elicited by several anorectic drugs

Several anorectic drugs affect dopamine metabolism in the rat striatum, increasing the concentration of homovanillic acid (HVA). However 1- and d-amphetamine and mazindol develop a tolerance to the HVA increase. On the contrary, the effect of fenfluramine and S 992 is not reduced by sub-chronic treatments. Moreover, a cross-tolerance to this biochemical effect develops between amphetamine and mazindol, but pretreatment with fenfluramine or with S 992 does not induce cross-tolerance to amphetamine.

Effects of drugs on the formation of homovanillic acid in the rat retina

Homovanillic acid (HVA) levels were measured in the eye and the corpus striatum of rats under normal conditions and after different drug treatments. Neuroleptic agents such as clozapine, cis-flupenthixol and haloperidol induced comparable increases in HVA levels, whereas the non-neuroleptic trans-isomer of flupenthixol was inactive in both structures. Apomorphine decreased HVA levels in the retina and the corpus striatum, while amphetamine induced a decreased HVA formation in the retina and did not change levels of HVA in the corpus striatum. Probenecid caused a similar percentage rise of HVA in both structures. Morphine and oxotremorine induced a rise in HVA levels in the corpus striatum but not in retinal samples.

Effects of mazindol, a non-phenylethylamine anorexigenic agent, on biogenic amine levels and turnover rate

1 Mazindol is a new anorexigenic agent which possesses a different chemical structure from that of phenylethylamines, but shows a pharmacological profile similar to that of (+)-amphetamine. 2 Mazindol neither altered whole brain monoamine levels (noradrenaline (NA), dopamine, 5-hydroxytryptamine (5-HT)) nor changed NA levels in the hypothalamus or dopamine levels in the caudate nucleus. 3 Mazindol enhanced dopamine turnover rate in the caudate nucleus, as shown by the increased rate of dopamine decline after blockade of catecholamine synthesis by alpha-methyl-p-tyrosine and decreased the conversion index of (3H)-tyrosine into brain NA. 4 Mazindol administration did not modify pargyline-induced decline of 5-hydroxyindoleacetic acid suggesting that 5-HT turnover is not altered by this drug.